Please make a donation to the Aplastic Anemia and MDS International Foundation.
Donate Today
Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Abstract The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to…
In this issue of Blood, Mushtaq et al1 report on a phase 1/2 trial (NCT05984199, known as Vor Biopharma trial VBP301) utilizing donor-derived anti-CD33 chimeric antigen receptor–modified (CAR) T cells (VCAR33) in patients with relapsed acute myeloid leukemia (AML) following…
Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…
ABSTRACT Regimens combining calcineurin inhibitors with methotrexate or mycophenolate have been the backbone for graft-versus-host disease (GVHD) prophylaxis. Early studies highlighted a delicate dose–response balance. The inclusion criteria comprised randomized clinical trials…
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) originates from hematopoietic stem cells (HSCs) harboring somatic mutations in the phosphatidylinositol glycan class A (PIGA) gene. Clonal expansion of PIGA-mutated cells occurs uniquely in the setting of bone marrow (BM) failure…
Background Paroxysmal nocturnal hemoglobinuria (PNH) clones are detected in up to 60% of patients with aplastic anemia (AA); however, their prognostic impact remains incompletely defined, particularly in the context of frontline immunosuppressive therapy (IST) or allogeneic…
Abstract Myelodysplastic neoplasms, also known as myelodysplastic syndromes (MDS), are a heterogeneous group of myeloid malignancies characterized by ineffective haematopoiesis, cytopenias and a variably increased risk of progression to acute myeloid leukaemia. MDS primarily…
ABSTRACT The prognostic value of NPM1-mut Measurable Residual Disease (MRD) has been increasingly recognized. However, real-world data validating the prognostic impact of NPM1-mut MRD remains limited. The aim of this study was to assess the prognostic value of NPM1-mut MRD and to…
Key Points aGVHD causes loss of gastric stem cells, G-cells, and PCs, leading to increased gastric pH. Pentagastrin therapy repairs stem cell and PC deficits, reverses pH changes, and reduces aGVHD damage, improving survival. Abstract Acute graft-versus-host disease (aGVHD) is a…
Patients who receive hematopoietic stem cell transplants are at risk of developing graft-versus-host disease (GVHD), where the immune cells descended from the transplanted stem cells attack the transplant recipient’s own tissues. Acute GVHD (aGVHD) is often treated with…